Today: 29 April 2026
Browse Category

NASDAQ:IONS 22 August 2025 - 25 August 2025

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····

Stock Market Today

  • First Trust Mortgage Income Fund (FMY) Ex-Dividend Reminder May 1, 2026
    April 29, 2026, 11:02 AM EDT. First Trust Mortgage Income Fund (FMY) will trade ex-dividend on May 1, 2026, with a monthly dividend of $0.065 payable May 15. The dividend yield is about 0.55% based on FMY's recent stock price of $11.92, implying a likely share price drop of similar magnitude on ex-dividend date. FMY's annualized yield stands at 6.54%, with a 52-week trading range between $11.40 and $12.39, and a last trade price near $12.04. Shares were down approximately 0.3% during the latest session. The data helps assess dividend sustainability and expected future yield for investors in this mortgage income fund.

Latest article

Vertiv Just Bought A Liquid-Cooling Specialist As AI Data Centers Turn Up The Heat

Vertiv Just Bought A Liquid-Cooling Specialist As AI Data Centers Turn Up The Heat

29 April 2026
Vertiv Holdings Co acquired Strategic Thermal Labs, a Texas-based liquid-cooling specialist, to boost its AI and high-performance computing data center offerings. Vertiv shares rose 0.6% to $307.00, valuing the company at about $119.9 billion. Deal terms were not disclosed. The move follows a 30% jump in Vertiv’s first-quarter net sales and an increased 2026 earnings forecast.
NIO Stock Jumps After Onvo L80 Debut: New SUV Puts China EV Maker Back in the Fight

NIO Stock Jumps After Onvo L80 Debut: New SUV Puts China EV Maker Back in the Fight

29 April 2026
NIO’s Hong Kong shares rose 8.7% after its Onvo unit began pre-sales for the L80 large electric SUV, starting at 245,800 yuan or 159,800 yuan with battery leasing. The launch follows NIO’s first quarterly net profit and aims at boosting volume in China’s crowded EV market. Test drives begin May 1, with the official launch set for May 15.
Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

Enphase Energy, Inc. Stock Slides as Q1 Reveals a Solar Demand Hangover

29 April 2026
Enphase Energy shares dropped 7.3% to $31.80 after reporting a first-quarter revenue decline to $282.9 million and a GAAP loss of $7.4 million. U.S. revenue fell 23% from the prior quarter, with sell-through demand down 48% sequentially. Adjusted earnings beat estimates, but investors appeared unconvinced demand had stabilized. SolarEdge and Sunrun shares also fell in early trading.
Go toTop